Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) EV-to-FCF : -0.11 (As of May. 24, 2024)

Advanced Proteome Therapeutics EV-to-FCF Chart

Advanced Proteome Therapeutics Annual Data
	Trend	Jul13	Jul14	Jul15	Jul16	Jul17	Jul18	Jul19	Jul20	Jul21	Jul22
EV-to-FCF		Get a 7-Day Free Trial					-4.28	-1.29	-1.13	-15.14	-3.49

Advanced Proteome Therapeutics Quarterly Data
	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23
EV-to-FCF	Get a 7-Day Free Trial															-3.88	-3.49	-0.03	0.16	-0.35

Competitive Comparison of Advanced Proteome Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Advanced Proteome Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Proteome Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Proteome Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Advanced Proteome Therapeutics's EV-to-FCF falls into.

Advanced Proteome Therapeutics EV-to-FCF Calculation

Advanced Proteome Therapeutics's EV-to-FCF for today is calculated as:

Advanced Proteome Therapeutics's current Enterprise Value is $0.14 Mil.
Advanced Proteome Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced Proteome Therapeutics  (OTCPK:APTCF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Advanced Proteome Therapeutics's PE Ratio for today is calculated as:

Advanced Proteome Therapeutics's share price for today is $0.0002.
Advanced Proteome Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.

Advanced Proteome Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description